AU709196B2 - Use of alendronate for the prevention of osteoporosis - Google Patents

Use of alendronate for the prevention of osteoporosis Download PDF

Info

Publication number
AU709196B2
AU709196B2 AU58824/96A AU5882496A AU709196B2 AU 709196 B2 AU709196 B2 AU 709196B2 AU 58824/96 A AU58824/96 A AU 58824/96A AU 5882496 A AU5882496 A AU 5882496A AU 709196 B2 AU709196 B2 AU 709196B2
Authority
AU
Australia
Prior art keywords
alendronate
salt
osteoporosis
woman
postmenopausal woman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU58824/96A
Other languages
English (en)
Other versions
AU5882496A (en
Inventor
Ashley J Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5882496A publication Critical patent/AU5882496A/en
Application granted granted Critical
Publication of AU709196B2 publication Critical patent/AU709196B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU58824/96A 1995-06-02 1996-05-29 Use of alendronate for the prevention of osteoporosis Ceased AU709196B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45819595A 1995-06-02 1995-06-02
US08/458195 1995-06-02
PCT/US1996/007912 WO1996038156A1 (en) 1995-06-02 1996-05-29 Use of alendronate for the prevention of osteoporosis

Publications (2)

Publication Number Publication Date
AU5882496A AU5882496A (en) 1996-12-18
AU709196B2 true AU709196B2 (en) 1999-08-26

Family

ID=23819759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58824/96A Ceased AU709196B2 (en) 1995-06-02 1996-05-29 Use of alendronate for the prevention of osteoporosis

Country Status (21)

Country Link
EP (1) EP0828496A1 (no)
JP (1) JPH10506648A (no)
KR (1) KR19990022436A (no)
CN (1) CN1192685A (no)
AU (1) AU709196B2 (no)
BG (1) BG63103B1 (no)
BR (1) BR9609020A (no)
CA (1) CA2222318A1 (no)
CZ (1) CZ381197A3 (no)
EA (1) EA000677B1 (no)
EE (1) EE03306B1 (no)
HU (1) HUP9900659A3 (no)
IL (1) IL118422A0 (no)
IS (1) IS4617A (no)
NO (1) NO975527D0 (no)
NZ (1) NZ308935A (no)
PL (1) PL323669A1 (no)
SK (1) SK159597A3 (no)
TR (1) TR199701482T1 (no)
WO (1) WO1996038156A1 (no)
ZA (1) ZA964465B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
KR102472749B1 (ko) * 2022-01-18 2022-12-02 주식회사 위엔씨 유해가스제거 및 항균탈취기능을 함유한 흡착소재 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations

Also Published As

Publication number Publication date
CA2222318A1 (en) 1996-12-05
AU5882496A (en) 1996-12-18
NO975527L (no) 1997-12-01
NZ308935A (en) 2000-07-28
IS4617A (is) 1997-11-19
KR19990022436A (ko) 1999-03-25
SK159597A3 (en) 1998-06-03
EP0828496A1 (en) 1998-03-18
HUP9900659A2 (hu) 2001-04-28
BR9609020A (pt) 1999-07-06
BG102060A (en) 1998-07-31
BG63103B1 (bg) 2001-04-30
CN1192685A (zh) 1998-09-09
HUP9900659A3 (en) 2002-12-28
TR199701482T1 (xx) 1998-03-21
PL323669A1 (en) 1998-04-14
EA000677B1 (ru) 2000-02-28
CZ381197A3 (cs) 1998-06-17
NO975527D0 (no) 1997-12-01
IL118422A0 (en) 1996-09-12
ZA964465B (en) 1996-12-11
JPH10506648A (ja) 1998-06-30
WO1996038156A1 (en) 1996-12-05
EE03306B1 (et) 2000-12-15
EA199700449A1 (ru) 1998-06-25

Similar Documents

Publication Publication Date Title
FI118296B (fi) Oraalisia nestemäisiä alendronaattikokoonpanoja
AU2006213981A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
ZA200206551B (en) Drospirenone for hormone replacement therapy
EA000964B1 (ru) Способ лечения или предупреждения остеопороза
AU690431B2 (en) Method of lessening the risk of non-vertebral bone fractures
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
AU709196B2 (en) Use of alendronate for the prevention of osteoporosis
US20020169148A1 (en) Use of alendronate for the prevention of osteoporosis
AU703887B2 (en) Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
AU713824B2 (en) Prevention of tooth loss by the administration of alendronate or its salts
KR19980702209A (ko) 척추 골절의 위험을 경감시키는 방법
AU692155B2 (en) Method and composition for treatment of osteoporosis
Standard Pr TEVA-RISEDRONATE
MXPA97009426A (en) Use of alendronate to prepare compositions for the prevention of osteoporo
JPH0132804B2 (no)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
CN115335038A (zh) 用于治疗痛经和/或经前期综合征(pms)的药物组合物
CN1187130A (zh) 用二磷酸盐预防与免疫抑制疗法有关的骨损失
MXPA97009906A (en) Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres
MXPA97006277A (en) The use of alendronate to prepare compositions to reduce the risk of non-vertebrate bit fractures
MXPA98001222A (en) Quecontain composition mefenamic acid in association with code

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired